Complement factor D inhibitors (e.g., lampalizumab and other anti-CFD biologics) have been demonstrated to reduce geographic atrophy progression in AMD, and comparable anti-complement strategies are under investigation in CKD to curb chronic inflammation. Here, CFD is linked to age-related macular degeneration.